insights_auto
Why is GNLX down ၇.၉၄%?
Dive Deeperchevron_right
GNLX:NASDAQ
Genelux Corp
၂.၃၂ US$
arrow_downward
-၇.၉၄%(-၀.၂၀) 1D
၂.၃၅ US$
arrow_upward
+၁.၂၉% (+၀.၀၃၀)bedtimeAfter hours
Closed: အောက် ၁၄, GMT-၄ ၁၆:၀၀:၀၁ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
၂.၄၈ US$
High
၂.၅၂ US$
Low
၂.၃၂ US$
Mkt. cap
၁၀.၅၀ ကုဋေ
Avg. vol.
၂.၄၃ သိန်း
Volume
၀.၀၀
52-wk high
၈.၅၄ US$
52-wk low
၂.၂၉ US$
EPS
-၀.၈၇ US$
Beta
၀.၅၉
Shares outstanding
၄.၅၂ ကုဋေ
No. of employees
၂၆
Open
၂.၄၈ US$
High
၂.၅၂ US$
Low
၂.၃၂ US$
Mkt. cap
၁၀.၅၀ ကုဋေ
Avg. vol.
၂.၄၃ သိန်း
Volume
၀.၀၀
52-wk high
၈.၅၄ US$
52-wk low
၂.၂၉ US$
EPS
-၀.၈၇ US$
Beta
၀.၅၉
Shares outstanding
၄.၅၂ ကုဋေ
No. of employees
၂၆
News stories
From web sources and news partners
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၃ မိနစ်
Is GRAIL (GRAL) Still Below Fair Value As Fresh Galleri Data Nears?
Benzinga
·
ပြီးခဲ့သည့် ၃၁ မိနစ်
RedCloud Holdings Shares Rise 18.40% After Hours - RedCloud Holdings (NASDAQ:RCT)
Stocktwits
·
ပြီးခဲ့သည့် ၄ နာရီ
SKHY Tracks Worst Month Since Nasdaq Debut: SK Hynix Reportedly Wants To Ship More Chip Tools To China Before Building In US
Investor's Business Daily
·
ပြီးခဲ့သည့် ၄ နာရီ
Tech Futures Fall; Anthropic Revenue Jumps, But Not Enough?
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees၂၆
Founded၂၀၀၁
HeadquartersWestlake Village, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitegenelux.com